Ep. 53 - Bob Nelsen on AI, China and the IRA

04/17/24 • 35 min

This is a previously recorded episode of The BioCentury Show. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes.
In a wide-ranging conversation with BioCentury, Bob Nelsen, co-founder and managing director of Arch Venture Partners, said he is excited by the potential for AI to “create a language of biology,” is cautious about investing in China given increasing geopolitical tensions, and is convinced that the U.S. healthcare system could do a far better job of delivering on the promise of rapidly progressing science.
Nelsen, who has helped finance and create more than 150 companies, including 47 that have reached valuations exceeding $1 billion, discussed his conviction that focusing on creating transformational medicines, rather than looking for short-term gains, is a key to success in the life sciences.
View full story: https://www.biocentury.com/article/651502
#biotech #pharma #biopharma #TheBioCenturyShow
00:00 - Intro
02:00 - The Promise of AI
08:37 - The Inflation Reduction Act
15:50 - China
26:04 - Building Companies Around Big challenges

Next Episode

Ep. 57 - BMS's Robert Plenge: Causal biology is the North Star of R&D

This is a previously recorded episode of The BioCentury Show. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes.
Within the framework of target, modality and path to clinic, causal biology is the axis along which Head of Research Robert Plenge is building and prosecuting research at Bristol Myers. It maps from late-stage decisions the company has made, such as the Karuna acquisition, to strategies in early R&D, such as how to innovate in ADCs and extend the modality to new applications.
In conversation with Editor in Chief Simone Fishburn on The BioCentury Show, Plenge outlined his view of causal biology as a principal axiom for building an R&D engine to maximize probability of success. It is the foundation for step one — picking the right target — and sets the basis for the second and third tenets of his framework, finding the right therapeutic modality for a mechanism of action, and establishing a clear path to clinical proof of concept.
View full story: https://www.biocentury.com/article/652135
#biotech #biopharma #pharma #lifescience
00:00 - Intro
01:53 - BMS's Framework for Research
12:38 - First vs. Best in Class
16:09 - Modalities & Manufacturing
19:48 - CAR Ts & Autoimmunity
24:34 - ADCs